TY  - JOUR
T1  - Divergences in Antiviral Therapy for Diabetic Patients with COVID-19
A1  - Andreea Fitero
A1  - Nicoleta Negruț
A1  - Delia Carmen Nistor Cseppento
A1  - Delia Mirela Tit
A1  - Paul Andrei Negru
A1  - Cristian Bustea
A1  - Andrei Flavius Radu
A1  - Simona Gabriela Bungau
JF  - Pharmacophore
JO  - Pharmacophore
SN  - 2229-5402
Y1  - 2024
VL  - 15
IS  - 2
DO  - 10.51847/pERPVY0am7
SP  - 79
EP  - 89
N2  - Patients with diabetes are particularly susceptible to COVID-19 infection, which can result in severe respiratory illness. This study conducted a comparative assessment of the impact of antiviral therapy using molnupiravir and favipiravir in COVID-19 patients with underlying diabetes. A cohort of one hundred individuals infected with SARS-CoV-2, diagnosed with diabetes, and consecutively admitted, was included in the present study. These patients were treated with antivirals according to local guidelines: Group F (51 cases) was treated with favipiravir – 10 days and Group M (49 cases) was treated with molnupiravir – 5 days. In Group F, the average hospitalization was higher than in Group M (11.29±2.27 vs. 7.14±3.16, p
UR  - https://pharmacophorejournal.com/article/divergences-in-antiviral-therapy-for-diabetic-patients-with-covid-19-1kxm8zqmkjmhayt
ER  -